LGLucia Garcia-Collado

Lucia Garcia-Collado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lucia Garcia-Collado has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Deep Learning-Based Tool for Segmentation and Quantification of i-IFTA, Focal Infiltrates, and Tubular Dilation in Haematoxylin–Eosin-Stained Renal Whole-Slide Images

    by Joana Mercado-Hernández, David Martín-Calvo, Giada Carniglia, Noelia Díaz-Morales, Annette Düwell, Isabel Fuentes-Calvo, Lucía García Collado, Andriy Kovalchuk, Francisco J. López-Hernández, Nuria Martín-Fernández, et al.

    (1) Background: Simultaneous evaluation of acute and chronic lesions is critical for staging renal disease, yet manual assessment suffers from high inter-observer variability and heavy workloads. While deep learning models excel at structural segmentation, none currently consolidate the concurrent quantification of key AKI-to-CKD transition markers on standard-stained tissue slides. (2) Methods: We developed a U-Net-based convolutional neural network for the pixel-wise segmentation and quantification of inflammation-associated interstitial fibrosis and tubular atrophy (i-IFTA), focal inflammatory infiltrates and tubular dilation in haematoxylin–eosin-stained whole-slide images (WSIs) from rat models of renal injury. (3) Results: The model demonstrated robust pixel-wise segmentation in H&E-stained rodent renal tissue (overall accuracy: 88.26%, macro-averaged Dice coefficient: 0.843; per-class Dice ranging from 0.727 for focal infiltrates to 0.920 for unaltered tissue). While comparative evaluation against human annotators was performed on a limited patch subset, the model exhibited agreement trends close to expert pathologists and superior to junior annotators. The end-to-end WSI inference pipeline generates full-slide visual overlays and automated WSI-level quantitative area measurements in a mean time of 103.57 s per WSI on GPU hardware. (4) Conclusions: This model offers an objective and automated framework for quantifying key structural and inflammatory lesions in rodent renal tissue. By enabling rapid WSI-level quantitative area measurements, it establishes a solid foundation for preclinical histopathological assessment and provides high potential for future translation into human clinical pathology.

  • Open Access

    Correction: Gonzalez-Sanchez et al. Epithelial to Mesenchymal Transition Transcriptional Regulator ZEB1 in Liver Cancer: Oncogenic Roles and Therapeutic Potential. Int. J. Mol. Sci. 2025, 26, 11135

    by Ester Gonzalez-Sanchez, Carlos Andres Roldan-Hernandez, Ana Martin-Ramirez, Lucia Garcia-Collado, Laura Fouassier, Javier Vaquero

    The following reference [84] has been retracted and has to be removed from the original publication

  • Open Access

    A Deep Learning-Based Tool for Segmentation and Quantification of i-IFTA, Focal Infiltrates, and Tubular Dilation in Haematoxylin-Eosin Stained Renal Whole-Slide Images

    by Joana Mercado-Hernández, David Martín-Calvo, Giada Carniglia, Noelia Díaz-Morales, Annette Düwell, Isabel Fuentes-Calvo, Lucía García Collado, Andriy Kovalchuk, Francisco J. López-Hernández, Nuria Martín-Fernández, et al.

    Simultaneous evaluation of acute and chronic lesions is critical for staging renal disease, yet manual assessment suffers from high inter-observer variability and heavy workloads. While deep learning models excel at structural segmentation, none currently consolidate the concurrent quantification of key AKI-to-CKD transition markers in standard stains. We developed a modified U-Net convolutional neural network for the pixel-wise segmentation and quantification of inflammation-associated interstitial fibrosis and tubular atrophy (i-IFTA), focal inflammatory infiltrates and tubular dilation in haematoxylin-eosin-stained whole-slide images (WSIs) from rat models of renal injury. The model achieved an overall test accuracy of 90.21% (weighted F1-score: 90.22%). Per-class F1-scores ranged from 0.73 for focal infiltrates to 0.94 for unaltered tissue, mirroring biological class distributions. Expert pathologists validated the high quality of the boundaries, which was comparable to junior-level annotations. The end-to-end inference pipeline successfully generates full-slide visual overlays and automated quantitative area metrics in a mean time of 215 seconds per WSI on standard CPU hardware. This model addresses a critical gap by simultaneously quantifying key structural and inflammatory lesions in H&E tissue. By reducing evaluation times from hours to minutes, it offers a scalable, reproducible tool to standardize histopathological assessment.

  • Open Access

    Inhibition of the ZEB1–BCL2 axis in cancer-associated fibroblasts as a strategy to improve chemotherapy response in intrahepatic cholangiocarcinoma

    by Ester Gonzalez-Sanchez, Marie Vallette, Lucia Garcia-Collado, Aashreya Ravichandra, Mirko Minini, Allan Pavy, Josep Amengual, Carlos Andres Roldán-Hernández, Ana Martin Ramirez, Corentin Louis, et al.

  • Open Access

    Epithelial to Mesenchymal Transition Transcriptional Regulator ZEB1 in Liver Cancer: Oncogenic Roles and Therapeutic Potential

    by Ester Gonzalez-Sanchez, Carlos Andres Roldan-Hernandez, Ana Martin-Ramirez, Lucia Garcia-Collado, Laura Fouassier, Javier Vaquero

    Zinc finger E-box binding homeobox 1 (ZEB1) is a member of the zinc finger homeodomain transcription factor family, with a pivotal role in regulating the epithelial to mesenchymal transition (EMT) process. Increasing evidence suggests that ZEB1 is overexpressed in liver tumors, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), and it correlates with advanced disease features and reduced overall survival. Here, we examine ZEB1 molecular functions, regulatory networks and contribution to tumorigenesis. We also discuss the emerging therapeutic strategies and future research directions aimed at targeting the ZEB1 molecular network to improve the outcome of liver cancer patients.